ProSciento organized and funded the formation of the “NASH Roundtable,” a collaborative forum of leading academic and clinical developments experts designed to advise drug development programs, according to a press release.
“Nonalcoholic steatohepatitis is a serious disease with currently no approved therapies for patients, in part while the scientific and clinical research communities are still working towards robust clinical and regulatory development frameworks,” Marcus Hompesch, MD, CEO of ProSciento, said in the release. “The NASH Roundtable provides a forum for thought leaders in hepatology, endocrinology and clinical research working collaboratively to optimize early and later stage clinical development efforts and advise on promising therapeutic programs for biopharma.”
Along with Hompesch, the NASH Roundtable co-chairs include Rohit Loomba, MD, founding director of the NAFLD Translational Research Unit at the University of California in San Diego, and Arun Sanyal, MD, FAASLD, Z. Reno Vlahcevic professor of medicine at Virginia Commonwealth University School of Medicine.
Additional members of the NASH Roundtable include:
- Kenneth Cusi, MD, from the University of Florida;
- Vlad Ratziu, MD, PhD, from Sorbonne University in France;
- Mary Rinella, MD, from Northwestern University in Illinois;
- Manuel Romero-Gómez, MD, from the University of Seville in Spain; and
- Detlef Schuppan , MD, PhD, from Mainz University Medical Center in Germany.
“There's a tremendous need to find clinical solutions for NAFLD and NASH patients,” Loomba said in the release. “Our goal with the NASH Roundtable is to facilitate systematic, focused collaboration that accelerates progress in vital academic research and promising drug development programs.”
ProSciento will announce additional members in the coming weeks. Additionally, the NASH Roundtable will meet biannually at AASLD’s The Liver Meeting and EASL’s International Liver Congress.